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Abstract
To address the increasing burden of diabetes in New York City, we designed 2 electronic health records (EHRs)-
facilitated diabetes management systems to be implemented in 6 primary care practices on the West Side of 
Manhattan, a standard system and an enhanced system. The standard system includes screening for diabetes. The 
enhanced system includes screening and ensures close patient follow-up; it applies principles of the chronic care 
model, including community–clinic linkages, to the management of patients newly diagnosed with diabetes and 
prediabetes through screening. We will stagger implementation of the enhanced system across the 6 clinics allowing 
comparison, through a quasi-experimental design (pre–post difference with a control group), of patients treated in the 
enhanced system with similar patients treated in the standard system. The findings could inform health system 
practices at multiple levels and influence the integration of community resources into routine diabetes care.
Introduction
Significant progress has been made in controlling type 2 diabetes and its complications in primary care settings 
through the application of the chronic care model (CCM) (1–3). Evidence that CCM modifications to primary care 
practice can prevent type 2 diabetes is limited (4–6). Screening high-risk patients to detect diabetes and prediabetes 
was cost-effective (7–9), and prevention of type 2 diabetes in people with prediabetes through adoption of appropriate 
lifestyle changes and pharmacologic interventions has been successful in experimental settings (10). However, ongoing 
challenges in translating this evidence into primary care practice include the identification of appropriate target 
populations and the difficulty of incorporating time- and resource-intensive lifestyle interventions into routine clinical 
care (6). Although community and peer support systems have proven effective in preventing many chronic diseases 
(11,12), rigorous evaluations of integrated health care systems and community linkages for preventing type 2 diabetes 
are lacking (13).
Six clinics in a primary care network in New York City, 3 of which are federally qualified health centers, have 
established an evidence-based diabetes management system grounded in CCM principles in the context of developing 
a patient-centered medical home in each clinic (14). As defined by the National Committee for Quality Assurance, a 
patient-centered medical home is a health care setting that facilitates partnerships between patients and their 
physicians through the use of registries, information technology, and health information exchange. Our study will 
examine a standard and an enhanced diabetes management system. The standard system, already implemented, 
includes an electronic health records (EHR)-based, targeted screening program that is aimed at detecting previously 
undiagnosed diabetes (hemoglobin A1c [HbA1c] > 6.5%) and prediabetes (HbA1c 5.7%–6.4%). The enhanced diabetes 
management system is designed to facilitate the management of patients identified through the screening program as 
having diabetes or prediabetes. The enhanced system, which extends components of the CCM including community–
clinic linkages to patient management, will be added to the standard system. The staggered implementation of the 
enhanced system across the 6 target clinics will allow comparisons of participant outcomes in the enhanced versus 
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standard clinics through a quasi-experimental design (pre–post difference with a control group) by retrospective 
analyses of the data extracted from the EHR. The primary objective of these analyses is to test 3 hypotheses: first, that 
patients with newly diagnosed diabetes or prediabetes who will be exposed to the enhanced system will be more likely 
than patients exposed to the standard system to experience a reduction in HbA1c levels over 12 months; second, that 
any reductions in HbA1c levels observed in patients in the enhanced system will be sustained over a follow-up period 
of 30 months; and third, that patients in clinics adopting the enhanced system will be retained longer in appropriate 
health care than those in the standard system.
Study Population
Patients seen in the 6 primary care clinics of the New York City health care system included in our study receive care 
that includes diabetes screening and management as determined by their health care provider. All patients who visit 
these clinics over a 6-month baseline period, are at least 18 years of age, and have not been previously diagnosed with 
diabetes are eligible for our study (15). Through an EHR-facilitated screening system (9,16,17), patients we identify as 
at risk for diabetes by American Diabetes Association (ADA) criteria (16) are referred for HbA1c tests. Those patients 
determined to have prediabetes (HbA1c 5.7–6.4%) or new-onset diabetes (HbA1c >6.5%) will be included in the study 
sample (15,16,18). All 6 clinics have patient populations with roughly similar sociodemographic and clinical 
characteristics.
Study Design
All 6 clinics incorporated the standard diabetes management system over the first 6 months of 2012. Two clinics have 
been selected to start implementing the enhanced system within the following 6 months (from July through December 
2012). For 12 months following implementation, these 2 clinics will use the enhanced system with all patients, while 
the remaining 4 clinics continue to use the standard system) until month 15 when they will also implement the 
enhanced system (Figure). We will follow all patients who meet study criteria and visit any of the 6 study clinics during 
the 6-month baseline period for a minimum of 30 months.
Page 2 of 8Preventing Chronic Disease | Expansion of Electronic Health Record-Based Screening, Pr...
Figure. Data activities timeline and clinical activities timeline for standard diabetes management system and 
enhanced diabetes management system. [A text description of this figure is also available.]
Follow-up care in the standard system conforms to recommendations for diabetes prevention and management (16); 
that is, patients with newly diagnosed diabetes are prescribed treatment and asked to return to the clinics every 3 to 6 
months to monitor progress. We will advise patients newly diagnosed with prediabetes of their diagnosis; advise them 
of ADA-recommended lifestyle changes (5) via an office visit, a telephone call, or mail; and ask them to return within 
12 months to assess progress in reducing HbA1c levels.
The enhanced system, in addition to the standard-system practices, fully incorporates CCM principles specific to the 
management of prediabetes. It addresses 1) care delivery and clinical information systems redesign (prediabetes-
Page 3 of 8Preventing Chronic Disease | Expansion of Electronic Health Record-Based Screening, Pr...
structured templates, planned visits, feedback on performance and point-of-care delivery prompts such as prediabetes 
order sets to ensure recommended clinical care); 2) decision support (education of physicians and ancillary staff in 
applying evidence-based prevention and treatment); and 3) patient self-management support (use of culturally 
appropriate tools, systematic referrals to established diabetes prevention programs in the community, and an 
inventory of available free or low-cost existing community resources that facilitate management of diabetes and 
prediabetes through lifestyle changes) (19,20). In the enhanced clinics, this self-management support system will also 
be available for patients with newly diagnosed diabetes. Patients with newly diagnosed prediabetes will be asked to 
return to the clinic within 6 months to monitor progress.
To ensure minimal losses to follow-up for our study, the staff in all 6 clinics will be instructed to contact all patients 
newly diagnosed with prediabetes or diabetes to ask them to return to clinic yearly.
Data Analysis
We will conduct retrospective analyses on routine clinical data extracted from the EHR (Appendix). We will perform 
both intent-to-treat analysis and an as-treated analysis. Mixed-effects models accounting for clustering of patients 
within clinics will be used in our analyses. Our primary outcome, percentage change in HbA1c, will test our primary 
hypothesis that reduction in HbA1c observed at 12 months following initiation of the enhanced system in the selected 
clinics will be greater than reduction in HbA1c during the same period in the standard clinics. We will compare 
baseline HbA1c values to the average of HbA1c values obtained during the 12-month follow-up period. We will use this 
same outcome to test our second hypothesis, that observed HbA1c improvements in the enhanced clinics will be 
sustained over 30 months. To test our third hypothesis, that patients in clinics adopting the enhanced system will have 
greater retention in the health care system during the 12-month follow-up period than those exposed to the standard 
system, we will assess number of visits to a primary care physician and number of HbA1c tests performed. This will be 
a natural experiment; therefore, we anticipate some differences in the sociodemographic and clinical characteristics of 
participants across clinics. We will use propensity score-matching (21) to adjust for these differences, selecting from a 
wide array of patient measures in the EHR, including demographics, insurance coverage, clinical diagnoses, laboratory 
tests results, and information on use of health care services.
Outcomes
This study will examine the effectiveness of an enhanced system for the management of newly diagnosed diabetes and 
prediabetes in participants identified through targeted screening in a primary care setting. This enhanced system will 
fully incorporate most components of the CCM (1,2) and as such, will involve policy changes at more than 1 level; 
however, its focus will be observation of the potential benefits of EHR in screening and monitoring outcomes and 
practice patterns (22). At the same time, this approach will involve a modest lifestyle change that leverages community
-based resources. Evidence is mixed for the efficacy of EHR-based interventions in improving care for patients already 
diagnosed with diabetes (23,24). The use of EHR for diabetes screening and prevention may improve outcomes, 
because each primary care visit can be considered an opportunity for immediate intervention (25). If the outcomes of 
our analyses are positive, attribution of an EHR effect independent of other components of the intervention could be 
addressed in future studies.
Our study will be among the first to address whether it is possible to prevent diabetes in a large urban population by 
implementing an approach that is initiated during routine clinical practices and maintained over time by patients. A 
successful outcome could prompt health systems, health plans, and public insurers to adopt policies such as changes in 
reimbursement and reallocation of resources to facilitate prevention and early control of diabetes in primary care 
practices. In addition, it could prompt key players in the community (public agencies, business leaders, social 
organizations) to adopt and support policies aimed at developing and sustaining effective and affordable lifestyle 
intervention programs and at maintaining strong clinic–community linkages.
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Appendix. Power and Statistical Analyses
Primary Analysis
Our primary outcome is defined as percent reduction in HbA1c. Baseline is the HbA1c measurement collected at the 
patient’s first visit, and we will obtain the baseline during the baseline period. This will be considered the pre-
intervention measure. Final HbA1c will be the mean of all HbA1c measurements collected in the follow-up period. This 
will be considered the postintervention measure. This measurement must be made at least 12 months and no more 
than 24 months after the baseline measurement (Figure). The main “exposure” for our primary analysis will be 
receiving care from a provider in an enhanced diabetes management system site versus receiving care from a provider 
in a standard diabetes management system site. Other measures to adjust for potential noncomparability between 
groups include information on participant demographics, insurance coverage, clinical diagnoses, laboratory test 
results, use of laboratory services, and other measures of health services use collected on electronic medical records, 
including patient age, race, sex, zip code of residence, diabetes diagnosis, risk factor information, and other clinical 
data such as body mass index, blood pressure, blood lipids, and creatinine.
Data Analysis
Our primary analysis will compare average change in participants’ HbA1c levels at the enhanced and standard sites 
during a 12-month period. For these analyses, the dependent variables will be baseline HbA1c and final HbA1c as 
defined above. Mixed-effects models accounting for clustering of patients within clinics will be constructed to test 
whether the average change in HbA1c is greater in the enhanced than in the standard system during a 12-month 
period. The models will include the following fixed effects: intervention type (eg, enhanced vs standard), time (baseline 
vs follow-up), and interaction effect (intervention by time). The models will include clinic and patient random effects 
to account for potential clustering among participants in the same clinic and between repeated measures in the same 
patient.
Because this is a natural experiment, we anticipate some differences in the sociodemographic and clinical 
characteristics of patients across clinics. We will use propensity score matching to adjust for these differences, 
selecting from a wide array of measures, which will be downloaded from our electronic health records (EHRs) to 
develop appropriate scores.
Missing Data
We anticipate few missing data points because our data will draw from an EHR system. However, when missing data 
occur, we will examine these data for potential bias in missingness and will apply 1 of several possible imputation 
methods on the basis of our initial evaluations of the nature and extent of missing data. Because we anticipate any 
missing data will follow a multivariate normal distribution, we will first consider a standard Markov Chain Monte 
Carlo method, and we will impute missing data multiple (at least 5) times to take into account the uncertainty of 
imputed values. On the basis of the nature and form of missing data, we will also consider the other 2 widely used 
imputation methods, the predictive method and the propensity score method.
Loss to Follow-up
In this design, loss to follow-up would include participants who drop out of care at the designated site (eg, move out of 
New York City), who do not keep any follow-up appointments within 12 months of an initial screening that yields 
positive results, or who do not have an HbA1c test.
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Power Analyses
Data from our EHR and published data from prior research (1) provided estimates for the following sample size 
calculations. These calculations were based on the method published by Heo and Leon (2). We applied the following 
outcome measure assumptions: 1) the log-transformed HbA1c measure (or other appropriate transformation) is 
approximately normally distributed; 2) the intraclass correlation of repeated HbA1c measures within a 12-month 
period is approximately 0.62; 3) the total population variance of HbA1c measures is 3.63; 4) the expected difference 
between the enhanced and standard systems in HbA1c change over 12 months is 0.3; and 5) there will be at least 2 
clinics per exposure group. We will allow an α-error level of .05, and we anticipate a very conservative rate of loss to 
follow up of 15.0%. Given these assumptions, we have an 80.0% power to detect an average difference between the 
enhanced and standard group of 0.158 if we obtain a sample size of 568 patients assigned to each diabetes 
management system. Given the size of our health care system, we anticipate obtaining a sample size at least this large 
during our data collection period.
Limitations
Because this is population-wide health services research, it is based on a nonrandomized design, leaving open the 
possibility of noncomparability between patients exposed to the enhanced system and those exposed to the standard 
system. Although we will consider this limitation as we conduct our analyses, biases and residual confounding are 
possible in this design. Participants at different practice sites are likely to differ in several ways. We will conduct 
subsequent analyses that examine each practice separately to make sure it is appropriate to combine these data. If not, 
separate results will be presented for each practice. However, this will reduce our power to detect a difference between 
the enhanced and standard systems.
Secondary Analyses
In addition to the primary data analyses described above, we will conduct 2 secondary analyses.
1) We will examine whether observed improvements in the mean response profile of HbA1c of the enhanced diabetes 
management system is sustained after the first 12 months of follow-up. Because the enhanced system will be 
introduced to the 4 clinics using the standard system only at month 15, we will no longer have an unexposed 
concurrent control group. However, the available data will be useful for examining long-term trends over time for a 
large patient population. For example, we anticipate that the HbA1c outcomes for patients will continue to improve or 
remain stable over the longer-term observation period.
The measures and statistical models we will use for this analysis will be the same as those used for the primary 
analysis. In addition, we will consider using a combination of statistical techniques to compare the rate of change in 
participant HbA1c levels before and after implementation of the management systems, including lowess plots to assess 
the general shape of the curves, splining to account for nonpolynomial trends in the data, and linear mixed effects 
models. These findings will help us to draw conclusions about the overall effect of our diabetes management systems in 
our participant population.
2) We will also test whether patients in clinics adopting the enhanced system will be retained longer in the health care 
system and have greater adherence to recommended health care during the 12-month period following initiation of 
this system compared with those exposed to the standard system. For this analysis, our outcomes will include number 
of visits to a primary care physician, number of HbA1c measurements obtained, and number of community resources 
used. Prevention strategies can lead to unneeded medical care, that is, overuse of services. It will be important to 
monitor such unintended consequences and the cost of our enhanced diabetes management system. For example, we 
will closely monitor the number of HbA1c tests recorded for patients once their HbA1c levels are categorized as normal 
to determine whether unnecessary follow-up testing is being performed.
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